CD24 and Miyoshi myopathy: In addition to solid tumors, CD24 has been identified as the most highly expressed immune checkpoint in leukemia stem cells (LSCs), and CD24+ multiple myeloma (MM) cells constitute a subtype of MM CSCs [38,39].